Population Pharmacokinetics of CC-122

Background: CC-122 is a cereblon-modulating agent that exerts direct cell-autonomous activity against malignant B cells and immunomodulatory effects. Herein, a population pharmacokinetic (popPK) model of CC-122 was developed and the influence of demographic and disease-related covariates on population pharmacokinetic parameters was assessed based on data from three clinical studies of CC-122 (dose range, 0.5-15 mg) in healthy subjects and cancer patients. Methods: Nonlinear mixed effects modeling was employed in developing a population pharmacokinetic model of CC-122 based on 298 patients from 3 clinical studies. Results: The PK of CC-122 was adequately described with a two-compartment model with first-order absorption and elimination. Tumor types were found to be significantly correlated with apparent clearance (CL/F) and apparent volume of distribution of the central compartment. Creatinine clearance was identified as a statistically significant covariate of CL/F. Sex and body weight were statistically but not clinically relevant on V2/F. Conclusion: In conclusion, the two-compartment model built can be used to adequately describe the time course of the population pharmacokinetics of CC-122 and should serve as the basis for dose adjustment decision-making of CC-122.

Automated summary

The population pharmacokinetics of CC-122 was adequately described by a two-compartment model with first-order absorption and elimination in 298 patients from 3 clinical studies. Tumor types were significantly correlated with apparent clearance and apparent volume of distribution of the central compartment, while creatinine clearance was identified as a statistically significant covariate of clearance. Sex and body weight were statistically but not clinically relevant on volume of distribution.